Background: The SARS-CoV-2 pandemic is characterized by multiple cases, and high rates of morbidity and mortality in individuals with predisposing risk factors. 1- to 50 people who have been infected with SARS-CoV-2 are thought to have developed post-COVID-19 symptoms. Several studies have recently indicated new-onset diabetes associated with COVID-19. Preliminary observations suggest that new-onset diabetes (NOD) after COVID-19 infection is a miracle. Objectives: This study focuses on the chain of events that follow infection with COVID-19. It is investigates the effects of infection-related onset diabetes, known as newly diagnosed diabetes (NDD). Methodology: This Study included 100 cases of females and males. It was confirmed that all patients were actually infected with Covid-19, which were part of the current prospective experimental study they were divided in three groups, after testing positively by a rapid antigen test or rapid antibody test. During the three-month follow-up, the cases that developed NOPD and NODM as well as the threat factors related to them were evaluated. Results: The first group whose HbA1c levels were examined actually developed diabetes (NOD) as a result of their infection with COVID-19 disease, the second group indicated that they were in the early stage of diabetes (NOPD); Cases diagnosed with NODM had an HbA1c > 6.4. The HbA1c range of 5.7 to 6.4 was utilized to describe NOPD, whereas the third group that was infected with Covid-19 and after that did not develop any form of diabetes. Conclusion: A considerable proportion of initial non-diabetic cases experienced new-onset hyperglycemia following COVID-19 infection.